Catalyst Pharms Drug Patent Portfolio
Catalyst Pharms owns 3 orange book drugs protected by 14 US patents Given below is the list of Catalyst Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11382922 | Aqueous oral pharmaceutical suspension compositions | 16 Jul, 2040 | Active |
| US11471471 | Aqueous oral pharmaceutical suspension compositions | 17 Mar, 2040 | Active |
| US10626088 | Determining degradation of 3,4-diaminopyridine | 25 Feb, 2037 | Active |
| US10793893 | Methods of administering 3,4-diaminopyridine | 26 May, 2034 | Active |
| US11690853 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | 07 Mar, 2033 | Active |
| US11060128 | Methods of administering 3,4-diaminopyridine | 29 Jun, 2032 | Active |
| US11268128 | Methods of administering 3,4-diaminopyridine | 29 Jun, 2032 | Active |
| US11274331 | Methods of administering 3,4-diaminopyridine | 29 Jun, 2032 | Active |
| US11274332 | Methods of administering 3,4-diaminopyridine | 29 Jun, 2032 | Active |
| US10857161 | Non-hormonal steroid modulators of NF-kB for treatment of disease | 28 May, 2029 | Active |
| US11833159 | Non-hormonal steroid modulators of NF-kB for treatment of disease | 28 May, 2029 | Active |
| US8334279 | Non-hormonal steroid modulators of NF-κB for treatment of disease | 28 May, 2029 | Active |
| US8772497 | Method for producing 1, 2-dihydropyridine-2-one compound | 01 Jul, 2026 | Active |
| US6949571 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof | 23 May, 2025 | Active |
Latest Legal Activities on Catalyst Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Catalyst Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 10 Jun, 2024 | US10857161 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 05 Jun, 2024 | US8334279 |
| Second letter to regulating agency to determine regulatory review period | 15 May, 2024 | US8334279 |
| Second letter to regulating agency to determine regulatory review period | 15 May, 2024 | US10857161 |
| Second letter to regulating agency to determine regulatory review period | 15 May, 2024 | US11690853 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 May, 2024 | US10857161 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 May, 2024 | US11690853 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 May, 2024 | US8334279 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 31 Mar, 2024 | US10793893 |
|
Patent Term Extension Certificate
Critical
| 11 Mar, 2024 | US6949571 |
|
PTE Interim Patent Extension filed
Critical
| 29 Feb, 2024 | US6949571 |
| Surcharge for late Payment, Small Entity | 04 Jan, 2024 | US10626088 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 04 Jan, 2024 | US10626088 |
| Initial letter Re: PTE Application to regulating agency | 22 Dec, 2023 | US10857161 |
| Initial letter Re: PTE Application to regulating agency | 22 Dec, 2023 | US8334279 |
Catalyst Pharms's Family Patents
Catalyst Pharms Drug List
Given below is the complete list of Catalyst Pharms's drugs and the patents protecting them.
1. Agamree
Agamree is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11382922 | Aqueous oral pharmaceutical suspension compositions |
16 Jul, 2040
(15 years from now)
| Active |
| US11471471 | Aqueous oral pharmaceutical suspension compositions |
17 Mar, 2040
(15 years from now)
| Active |
| US11690853 | Non-hormonal steroid modulators of NF-κβ for treatment of disease |
07 Mar, 2033
(8 years from now)
| Active |
| US10857161 | Non-hormonal steroid modulators of NF-kB for treatment of disease |
28 May, 2029
(4 years from now)
| Active |
| US11833159 | Non-hormonal steroid modulators of NF-kB for treatment of disease |
28 May, 2029
(4 years from now)
| Active |
| US8334279 | Non-hormonal steroid modulators of NF-κB for treatment of disease |
28 May, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Agamree's drug page
2. Firdapse
Firdapse is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10626088 | Determining degradation of 3,4-diaminopyridine |
25 Feb, 2037
(12 years from now)
| Active |
| US10793893 | Methods of administering 3,4-diaminopyridine |
26 May, 2034
(9 years from now)
| Active |
| US11060128 | Methods of administering 3,4-diaminopyridine |
29 Jun, 2032
(7 years from now)
| Active |
| US11268128 | Methods of administering 3,4-diaminopyridine |
29 Jun, 2032
(7 years from now)
| Active |
| US11274331 | Methods of administering 3,4-diaminopyridine |
29 Jun, 2032
(7 years from now)
| Active |
| US11274332 | Methods of administering 3,4-diaminopyridine |
29 Jun, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Firdapse's drug page
3. Fycompa
Fycompa is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8772497 | Method for producing 1, 2-dihydropyridine-2-one compound |
01 Jul, 2026
(1 year, 8 months from now)
| Active |
| US6949571 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
23 May, 2025
(7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fycompa's drug page